Drug resistance is a daunting challenge in the treatment of breast cancer (BC). Exosomes,
as intercellular communicative vectors in the tumor microenvironment, play an important role …

In addition to the contribution of cancer cells, the solid tumor microenvironment (TME) has a
critical role in determining tumor expansion, antitumor immunity, and the response to …

Tumor recognition by T cells is essential for antitumor immunity. A comprehensive
characterization of T cell diversity may be key to understanding the success of …

Introduction Advanced breast cancer (aBC) remains incurable and the quest for more
effective systemic anticancer agents continues. Promising results have led to the FDA …

Simple Summary We here show that CD169+ TAMs in primary breast tumors are associated
with tertiary lymphoid-like structures (TLLSs), Treg and Breg signatures, and a worse …

A lack of therapeutically targetable molecular alterations and its aggressive nature make
triple-negative breast cancer [TNBC] a challenging disease. Chemotherapy is standard of …

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated
with poor prognosis, early recurrence, and the lack of durable chemotherapy responses and …

Simple Summary Immune therapy is designed to stimulate tumoricidal effects in a variety of
solid tumors including breast carcinomas. However, the emergence of resistant clones leads …

Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast
cancers, and its poor response to treatment has been a major problem in the field of breast …

Background One of the front treatment regimens used for metastatic triple-negative breast
cancer (mTNBC) is treatment with programmed death-1 (PD-1) or programmed death ligand …